Specialty cancer diagnostics company Precipio,
Inc. (NASDAQ: PRPO) announces that Mr. Ron Andrews has joined
the company’s Board of Directors. As the company continues to build
its products division around commercializing the technologies it
has developed (such as HemeScreen and IV-cell), having additional
resources and experienced industry veterans to support management’s
goals is key to its success and ongoing growth.
Mr. Andrews brings a
wealth of experience in the diagnostics world, and specifically in
the areas of product development & commercialization. Some of
Mr. Andrews’ past experiences includes Chief Commercial Officer at
Roche Molecular; President of Genetic Science Division at Thermo
Fisher Scientific; President of the Medical Sciences Venture at
Life Technologies Corporation; and CEO of Clarient, which was
acquired by GE Healthcare for $580M in 2010.
“My life’s work in
oncology has focused on democratizing important academic
capabilities to empower community oncologists and pathologists with
diagnostic tools that enable accurate, rapid delivery of important
information allowing them to provide the best care for their
patient,” said Mr. Andrews. “I am excited to join the Precipio
board as the team embarks on that same mission for physicians
managing patients with various forms of blood cancers. HemeScreen
is a tremendous opportunity for the company, and I look forward to
advising Ilan and team as they execute on their vision.”
“The significance and
timing of Mr. Andrews joining the board cannot be understated,”
said Ilan Danieli, CEO of Precipio, Inc. “At a time when the
company is growing its products business and sees it as a key
driver of revenue and profitability, having Ronnie on our board
will provide invaluable support to management. I am delighted to
have Ronnie as part of the team.”
Mr. Mark Rimer,
Partner at Kuzari Group and one of the first backers and supporters
of Precipio since its inception ten years ago, will be stepping
down from his role as a director, and will remain as a board
observer. Mr. Rimer’s contributions have been paramount to getting
Precipio to where it is today, and company management is delighted
to see Mark will remain involved with the company.
“The work that
Precipio is doing today to build valuable diagnostic products that
will continue to drive the core mission of eradicating medical
misdiagnosis demonstrates enormous progress from the early days yet
is perfectly in line with the original vision for the company when
we first invested in this team ten years ago,” said Mark Rimer,
Partner at Kuzari Group. “I am proud to have worked with Ilan and
the Precipio management team as well as all our committed partners
at the universities, and I am thrilled that Ron is ready to bring
his commercial experience to Precipio at the start of the company’s
next phase of growth.”
“It is no exaggeration
to say that Precipio would not be where it is today if it weren’t
for the efforts and ongoing support of Mark and Kuzari Group,” said
Ilan Danieli, CEO of Precipio. “Mark is a friend, colleague, mentor
and a key member of the Precipio family, and we are honored to have
had him serve on the company’s board for this long. His
contributions will undoubtedly continue as an observer.”
About Precipio
Precipio has built a platform designed to
eradicate the problem of misdiagnosis by harnessing the intellect,
expertise and technology developed within academic institutions and
delivering quality diagnostic information to physicians and their
patients worldwide, as well as proprietary products that serve
laboratories worldwide. Through its collaborations with world-class
academic institutions specializing in cancer research, diagnostics
and treatment such as the Yale School of Medicine, Harvard’s
Dana-Farber Cancer Institute, and the University of Pennsylvania,
Precipio offers a new standard of diagnostic accuracy enabling the
highest level of patient care. For more information, please visit
www.precipiodx.com.
Please follow us on Twitter @PrecipioDx and on
Facebook.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, including, among others, statements related to
the expected or potential impact of the novel coronavirus
(COVID-19) pandemic, and the related responses of the government,
consumers, and the company, on our business, financial condition
and results of operations, and any such forward-looking statements,
whether concerning the COVID-19 pandemic or otherwise, involve
risks, assumptions and uncertainties. Except for historical
information, statements about future volumes, sales, growth, costs,
cost savings, margins, earnings, earnings per share, diluted
earnings per share, cash flows, plans, objectives, expectations,
growth or profitability are forward-looking statements based on
management’s estimates, beliefs, assumptions and projections. Words
such as “could,” “may,” “expects,” “anticipates,” “will,”
“targets,” “goals,” “projects,” “intends,” “plans,” “believes,”
“seeks,” “estimates,” “predicts,” and variations on such words, and
similar expressions that reflect our current views with respect to
future events and operational, economic and financial performance,
are intended to identify such forward-looking statements. These
forward-looking statements are only predictions, subject to risks
and uncertainties, and actual results could differ materially from
those discussed. Important factors that could affect performance
and cause results to differ materially from management’s
expectations, or could affect the company’s ability to achieve its
strategic goals, include the uncertainties relating to the impact
of COVID-19 on the company’s business, operations and employees and
the other factors that are described in the sections entitled “Risk
Factors” and “Management’s Discussion and Analysis” in the
company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2019, as updated from time to time in the company’s
Securities and Exchange Commission filings.
The company’s forward-looking statements in this
press release are based on management’s current views, beliefs,
assumptions and expectations regarding future events and speak only
as of the date of this release. The company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by the federal securities
laws.
Inquiries:
investors@precipiodx.com
+1-203-787-7888 Ext. 523
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Apr 2023 to Apr 2024